The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
Excellent performance from vaccines: up 26.9% on a comparable basis1 2005 adjusted earnings1 guidance raised Approval of Plavix® in Japan
Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).
Sanofi-aventis announced today the signature of an agreement to transfer its rights to Exuberaâ, an inhaled human insulin, to Pfizer.
Lyon, France 21 December 2005 Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteurs human vaccine products. Läs resterande pressmeddelande i
Vice President Communications sanofi pasteur: Alain BERNAL U. S. Media Relations: Len LAVENDA Tel.: +1 570 839 7187 - Fax: +1 570 839 0955 - Sanofi Pasteur Inc. - Discovery Drive - Swiftwater, PA 18370-0187 - USA - www.sanofipasteur.com ~ Data Show that the Vaccine Is Safe, Demonstrates Immunogenicity and Provides Future Direction For Development ~ Lyon, France December 15, 2005 Sano
Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen (TCH) with TAXOTERE® (docetaxel), the platinum salt carboplatin and HERCEPTIN® (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer Paris and San Antonio December 8th, 2005 The Breast Cancer International Research Group
Paris December 2, 2005 Sanofi-aventis announced today that the U.S Food and Drug Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere (docetaxel) Injection Concentrate, in combination with a current standard treatment (cisplatin and 5-fluorouracil) for advanced gastric cancer. The supplemental application is based on d
Studie visar att rimonabant signifikant reducerar kardiovaskulära och metabola riskfaktorer hos överviktiga och feta patienter Paris, Frankrike, 16 november 2005 Sanofi-aventis tillkännagav att resultaten från RIO-Lipidsstudien publicerades i dag i The New England Journal of Medicine. I studien undersöktes effekten av rimonabant hos patienter med övervikt och fetma samt avvikande blodfetter (
En stor undersökning som publiceras på World Diabetes Day 14 november 2005 visar att diabetiker i större utsträckning vill medverka vid beslut som rör behandlingen av sjukdomen. Paris, 14 november 2005 Resultaten av en undersökning som publiceras idag på World Diabetes Day visar att nästan 80% av allmänheten personligen känner någon som har diabetes. För närvarande finns fler än 194 miljon
Alain BERNAL Vice-President Corporate Communications Tel: + 33-(0)4-37-37-78-97 Fax: +33-(0)4-37-37-77 89 Len LAVENDA U.S. Media Relations Tel: +1-570-839-4446 Len.Lavenda@sanofipasteur.com ~ Influenza Vaccine Leader sanofi Pasteur Contributes to French Pandemic Preparedness ~ Lyon, France November 10, 2005 Following discussions which started a few months ago, sanofi pasteur,
Paris October 24, 2005- Effective october 2oo5, Jean-Yves Wessely is appointed Senior Vice President in charge of Winthrop, worldwide Generics Activities of sanofi-aventis, based in Paris. Jean-Yves Wessely, MD, brings with him a wealth of more than 25 years of experience in the pharmaceutical industry, as well as an intimate knowledge of Winthrop's key markets, having held several regional a
Paris, 2005-10-20: Adults with type 2 diabetes taking Exubera (insulin human) alone or in combination with diabetes pills achieved significantly greater reductions in blood sugar levels compared to patients taking pills alone, according to a new study published in the October issue of Annals of Internal Medicine. Läs mer i bifogad fil. See attached document.
Paris October 14, 2005 Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of EXUBERA (insulin human), an inhalable form of insulin, for the treatment of type 1 and type 2 diabetes. The proposed therapeutic indication for Exubera is for the treatment of adult pati
MICROBIOLOGICAL ACTIVITY OF TELITHROMYCIN AGAINST STREPTOCOCCUS PNEUMONIAE SHOWN SUPERIOR TO OTHER STANDARD FIRST LINE ANTIBIOTICS OVER 4-YEAR PERIOD New data demonstrates that in vitro activity of Ketek (telithromycin) remained consistently high on S. pneumoniae with at least 99.8% of the isolates being susceptible Paris, 20 September 2005 Data presented today at the 15th Annual Internati
INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER Interim analysis of more than 3,000 patients in BCIRG006 study also shows TAXOTERE® non-anthracycline-based chemotherapy combined with HERCEPTIN® improved disease-free surviv
Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv
Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products
I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel